Literature DB >> 23370853

Anti-citrullinated protein antibodies: role in pathogenesis of RA and potential as a diagnostic tool.

Sadaf Moeez1, Peter John, Attya Bhatti.   

Abstract

Rheumatoid arthritis is an autoimmune disorder which involves inflammation of the synovial tissue, leading to synovial proliferation, bone erosion and ultimately joint disability. It is a complex disorder, and the proper etiology is still unknown. Both environmental and genetic factors are responsible for the development of rheumatoid arthritis. Clinically, the disease is generally diagnosed by the presence of auto-antibodies like rheumatoid factor. But these are not specifically associated with rheumatoid arthritis. These are also present in patients with other autoimmune disorders and also in healthy persons. Citrullinated epitopes are shown to be more specific for rheumatoid arthritis. Citrullination normally occurs in cells undergoing apoptosis, and hence, citrullinated proteins are cleared from body and not encountered by immune system. However, in rheumatoid arthritis patients, these are not cleared. Anti-citrullinated protein antibodies are detectable in patients at risk of rheumatoid arthritis long before the onset of the disease. The concentration of which normally increases as the disease progress. Hence, these are important for diagnosis of rheumatoid arthritis. This review is focused on the importance of anti-citrullinated protein antibodies in disease pathogenesis and its importance in the diagnosis of rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23370853     DOI: 10.1007/s00296-012-2635-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  56 in total

1.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

2.  The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.

Authors:  Annette H M van der Helm-van Mil; Kirsten N Verpoort; Ferdinand C Breedveld; Tom W J Huizinga; René E M Toes; René R P de Vries
Journal:  Arthritis Rheum       Date:  2006-04

3.  Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.

Authors:  Sumeet Agrawal; Ramnath Misra; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2006-03-30       Impact factor: 2.980

4.  B cells are important as antigen presenting cells for induction of MHC-restricted arthritis in transgenic mice.

Authors:  Veena Taneja; Christopher J Krco; Marshall D Behrens; Harvinder S Luthra; Marie M Griffiths; Chella S David
Journal:  Mol Immunol       Date:  2007-02-14       Impact factor: 4.407

5.  Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.

Authors:  K N Verpoort; C M Jol-van der Zijde; E A M Papendrecht-van der Voort; A Ioan-Facsinay; J W Drijfhout; M J D van Tol; F C Breedveld; T W J Huizinga; R E M Toes
Journal:  Arthritis Rheum       Date:  2006-12

Review 6.  Prognostic criteria in rheumatoid arthritis: can we predict which patients will require specific anti-rheumatoid treatment?

Authors:  J R Kirwan; B Quilty
Journal:  Clin Exp Rheumatol       Date:  1997 May-Jun       Impact factor: 4.473

7.  Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis.

Authors:  Kristine A Kuhn; Liudmila Kulik; Beren Tomooka; Kristin J Braschler; William P Arend; William H Robinson; V Michael Holers
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

8.  Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study.

Authors:  E W Karlson; L B Chibnik; J Cui; R M Plenge; R J Glass; N E Maher; A Parker; R Roubenoff; E Izmailova; J S Coblyn; M E Weinblatt; N A Shadick
Journal:  Ann Rheum Dis       Date:  2007-07-31       Impact factor: 19.103

9.  Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.

Authors:  F A van Gaalen; S P Linn-Rasker; W J van Venrooij; B A de Jong; F C Breedveld; C L Verweij; R E M Toes; T W J Huizinga
Journal:  Arthritis Rheum       Date:  2004-03

10.  Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations.

Authors:  L De Rycke; I Peene; I E A Hoffman; E Kruithof; A Union; L Meheus; K Lebeer; B Wyns; C Vincent; H Mielants; L Boullart; G Serre; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

View more
  9 in total

1.  Rheumatic diseases and the microbiome.

Authors:  Robert Hal Scofield
Journal:  Int J Rheum Dis       Date:  2014-06       Impact factor: 2.454

2.  Practice guidelines for pharmacists: The pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.

Authors:  Carolyn Bornstein; Marie Craig; Diane Tin
Journal:  Can Pharm J (Ott)       Date:  2014-03

3.  Anti-cyclic citrullinated peptide antibody (ACPA) and Rheumatoid arthritis: Clinical relevance.

Authors:  Karthikeyan P Iyengar; Abhishek Vaish; Arvind Nune
Journal:  J Clin Orthop Trauma       Date:  2021-12-01

Review 4.  Molecular mechanisms for contribution of MHC molecules to autoimmune diseases.

Authors:  Ludvig M Sollid; Wouter Pos; Kai W Wucherpfennig
Journal:  Curr Opin Immunol       Date:  2014-09-15       Impact factor: 7.486

Review 5.  From autoinflammation to autoimmunity: old and recent findings.

Authors:  Francesco Caso; Luisa Costa; Valeria Nucera; Giuseppe Barilaro; Ignazio Francesco Masala; Rossella Talotta; Paolo Caso; Raffaele Scarpa; Piercarlo Sarzi-Puttini; Fabiola Atzeni
Journal:  Clin Rheumatol       Date:  2018-07-16       Impact factor: 2.980

6.  Affinity Purification and Comparative Biosensor Analysis of Citrulline-Peptide-Specific Antibodies in Rheumatoid Arthritis.

Authors:  Eszter Szarka; Petra Aradi; Krisztina Huber; Judit Pozsgay; Lili Végh; Anna Magyar; Gergő Gyulai; György Nagy; Bernadette Rojkovich; Éva Kiss; Ferenc Hudecz; Gabriella Sármay
Journal:  Int J Mol Sci       Date:  2018-01-22       Impact factor: 5.923

Review 7.  Molecular Imaging of Inflammatory Disease.

Authors:  Meredith A Jones; William M MacCuaig; Alex N Frickenstein; Seda Camalan; Metin N Gurcan; Jennifer Holter-Chakrabarty; Katherine T Morris; Molly W McNally; Kristina K Booth; Steven Carter; William E Grizzle; Lacey R McNally
Journal:  Biomedicines       Date:  2021-02-04

Review 8.  Exosome application in treatment and diagnosis of B-cell disorders: leukemias, multiple sclerosis, and arthritis rheumatoid.

Authors:  Mohsen Karami Fath; Jalil Azami; Niloofar Jaafari; Mahsa Akbari Oryani; Nafiseh Jafari; Alireza Karim Poor; Ali Azargoonjahromi; Mohsen Nabi-Afjadi; Zahra Payandeh; Hamidreza Zalpoor; Dariush Shanehbandi
Journal:  Cell Mol Biol Lett       Date:  2022-09-05       Impact factor: 8.702

9.  The Effect of Chinese Medicine Compound in the Treatment of Rheumatoid Arthritis on the Level of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies: A Systematic Review and Meta-Analysis.

Authors:  Xuan Tang; Zehao Liu; Zhihua Yang; Shengmei Xu; Maojie Wang; Xiumin Chen; Zehuai Wen; Runyue Huang
Journal:  Front Pharmacol       Date:  2021-06-30       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.